BNP Paribas Financial Markets’s CureVac CVAC Stock Holding History

BNP Paribas Financial Markets’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-36,334	Closed	-$164K	–	5883
2025 Q4	$164K	Sell	36,334 -294,181	-89%	-$1.51M	﹤0.01%	4146
2025 Q3	$1.78M	Buy	330,515 +77,053	+30%	+$417K	﹤0.01%	2691
2025 Q2	$1.38M	Buy	253,462 +28,939	+13%	+$115K	﹤0.01%	2717
2025 Q1	$622K	Buy	224,523 +52,841	+31%	+$184K	﹤0.01%	3059
2024 Q4	$585K	Buy	+171,682	New	+$495K	﹤0.01%	3190
2022 Q4	–	Sell	-41,936	Closed	-$330K	–	4181
2022 Q3	$330K	Buy	+41,936	New	+$489K	﹤0.01%	3246

BNP Paribas Financial Markets's CVAC Position: Q1 2026 in Review

BNP Paribas Financial Markets sold out of CureVac (CVAC) in Q1 2026, closing a stake of 36,334 shares — an estimated $164K sold.

BNP Paribas Financial Markets first reported a position in CVAC in Q3 2022 and held it in 6 quarters. The position peaked at $1.78M in Q3 2025. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.

BNP Paribas Financial Markets reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
BNP Paribas Financial Markets sold 36,334 CureVac shares in Q1 2026, an estimated $164K.
BNP Paribas Financial Markets first reported a position in CureVac in Q3 2022 and held it in 6 quarters.
BNP Paribas Financial Markets's CureVac position peaked at $1.78M in Q3 2025.
0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.